Jan Brancewicz

Mr. Jan Brancewicz

Cellis AG, Zürich, Switzerland
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
JBJan Brancewicz
Jan Brancewicz
NWNatalia Wójcik
Natalia Wójcik
ZSZuzanna Sarnowska
Zuzanna Sarnowska
JRJulia Robak
Julia Robak
MKMagdalena Krol
Magdalena Krol
Macrophages are highly adaptable immune cells capable of responding dynamically to diverse environmental cues. They are pivotal in maintaining homeostasis, orchestrating immune responses, facilitating tissue repair, and, under certain conditions, contributing to disease pathogenesis. This review delves into the complex biology of macrophages, highlighting their polarization states, roles in autoimmune and inflammatory diseases, involvement in cancer progression, and potential as therapeutic targets. By understanding the context-dependent functional plasticity of macrophages, we can better appreciate their contributions to health and disease, paving the way for innovative therapeutic strategies.

2 October 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
JBJan Brancewicz
Jan Brancewicz
PKPaulina Kucharzewska
Paulina Kucharzewska
Macrophages, the most abundant immune cells in many solid tumors, are no longer viewed solely as accomplices of cancer but as powerful therapeutic allies. This review charts the rapid rise of macrophage-based immunotherapies, from CD47/SIRPα checkpoint blockade and CAR-macrophages to macrophage-drug conjugates (MDCs). We emphasize emerging frontiers - RNA-based reprogramming, epigenetic modulation, small activating RNA and circRNA approaches, and macrophage-derived extracellular vesicles - that are redefining how tumor-associated macrophages can be targeted or harnessed. Distinct from earlier TAM reviews, we integrate outcomes from ongoing and completed clinical trials, highlight therapeutic platforms beyond classical depletion and polarization, and frame macrophages not only as targets but also as delivery vehicles. By spotlighting both innovative strategies and the challenges of moving them into the clinic, we aim to provide a forward-looking guide for researchers and clinicians shaping the next generation of cancer immunotherapy.

4 February 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
BTBartlomiej Taciak
Bartlomiej Taciak
MBMaciej Bialasek
Maciej Bialasek
MKMalgorzata Kubiak
Malgorzata Kubiak
IMIlona Marszalek
Ilona Marszalek
MGMalgorzata Gorczak
Malgorzata Gorczak
MKMagdalena Krol
Magdalena Krol
Treatment of solid tumors remains challenging and therapeutic strategies require continuous development. Tumor-infiltrating macrophages play a pivotal role in tumor dynamics. Here, we present a Macrophage-Drug Conjugate (MDC) platform technology that enables loading macrophages with ferritin-drug complexes. We first show that macrophages actively take up human heavy chain ferritin (HFt) in vitro via macrophage scavenger receptor 1 (MSR1). We further manifest that drug-loaded macrophages transfer ferritin to adjacent cancer cells through a process termed ‘TRAnsfer of Iron-binding protein’ (TRAIN). The TRAIN process requires direct cell-to-cell contact and an immune synapse-like structure. At last, MDCs with various anti-cancer drugs are formulated with their safety and anti-tumor efficacy validated in multiple syngeneic mice and orthotopic human tumor models via different routes of administration. Importantly, MDCs can be prepared in advance and used as thawed products, supporting their clinical applicability. This MDC approach thus represents a promising advancement in the therapeutic landscape for solid tumors.

18 June 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
MSMiaomiao Sun
Miaomiao Sun
MBMaciej Bialasek
Maciej Bialasek
MMMaud Mayoux
Maud Mayoux
MLMeng-Syuan Lin
Meng-Syuan Lin
ABAlicia Buck
Alicia Buck
TWTobias Weiss
Tobias Weiss
The treatment of solid tumors faces substantial hurdles because of inadequate drug delivery and the immunosuppressive tumor microenvironment. To address these challenges, we developed a therapeutic platform using macrophages loaded with ferritin-drug conjugates, referred to as macrophage-drug conjugates (MDC), and applied it to glioblastoma, an immunologically cold solid tumor. MDC loaded with ferritin-conjugated monomethyl auristatin E enabled efficient, cell contact–dependent transfer of the payload by a mechanism involving transfer of iron-binding proteins, from either mouse or human macrophages preferentially into glioma cells. This targeted delivery and therapeutic efficacy was demonstrated across in vitro coculture systems, ex vivo assays using dissociated glioblastoma patient tumor samples, and in vivo using orthotopic glioblastoma mouse models, all while maintaining a favorable preclinical safety profile evidenced by minimal systemic toxicity and localized drug biodistribution. Beyond direct tumor cell killing leading to significant tumor regression and prolonged survival in these models, MDC therapy reprogrammed the immunosuppressive tumor microenvironment. Immune profiling by spectral flow cytometry revealed enhanced infiltration and activation of cytotoxic T lymphocytes and B lymphocytes while reducing immunosuppressive regulatory T cells. This culminated in a robust, durable, T cell–dependent antitumor immune response, the necessity of which was confirmed through studies in immunodeficient mouse models and by lymphocyte depletion, and which conferred protection against tumor rechallenge. The combined cytotoxic and immunomodulatory effects highlight the potential of MDC therapy as a promising strategy for glioblastoma treatment and support its further clinical development.

29 June 2025 in Cells
Verified
Journal Article
Open access
PDF file
JBJan Brancewicz
Jan Brancewicz
IPIrena Barbara Padzińska-Pruszyńska
Irena Barbara Padzińska-Pruszyńska
MKMalgorzata Kubiak
Malgorzata Kubiak
PKPaulina Kucharzewska-Siembieda
Paulina Kucharzewska-Siembieda
Ovarian cancer is a leading cause of cancer-related deaths among women, with platinum resistance posing a significant challenge. Conventional therapies often fail in these cases, highlighting the urgent need for novel treatment approaches. Immunotherapy has emerged as a promising strategy, offering renewed hope for patients with platinum-resistant ovarian cancer (PROC). This review explores the current landscape of immunotherapies for PROC, discussing different approaches, their mechanisms of action, and the potential for overcoming the limitations of conventional treatments.

27 June 2024
Verified
Other
Closed access
MKMagdalena Krol
Magdalena Krol
TRTomasz Rygiel
Tomasz Rygiel
JBJan Brancewicz
Jan Brancewicz
KGKonrad Gabrusiewicz
Konrad Gabrusiewicz
WLWaldemar Lipinski
Waldemar Lipinski
BTBartlomiej Taciak
Bartlomiej Taciak